This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dattwyler, R. J.
Right arrow Articles by Luft, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dattwyler, R. J.
Right arrow Articles by Luft, B. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Feb 1996, 468-469, Vol 40, No. 2
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Clarithromycin in treatment of early Lyme disease: a pilot study

RJ Dattwyler, E Grunwaldt and BJ Luft
Lyme Disease Center, State University of New York at Stony Brook 11794- 8161, USA.

Forty-one patients with erythema migrans were enrolled in an open- labelled pilot study of oral clarithromycin, 500 mg twice daily for 21 days, for the treatment of early Lyme disease. Immediately posttherapy, pretreatment signs and symptoms resolved among 91% of the 33 evaluable patients. At 6 months, all 28 of the evaluable patients were well. Clarithromycin shows promise as an effective agent for the treatment of early Lyme disease and warrants further study.


This article has been cited by other articles:

  • Tibbles, C. D., Edlow, J. A. (2007). Does This Patient Have Erythema Migrans?. JAMA 297: 2617-2627 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»